Valuation: Rallybio Corporation

Market Cap 90.7M 80.59M 75.22M 68.56M 129M 8.72B 131M 910M 353M 4.46B 341M 333M 14.31B P/E 2026 *
-4.64x
P/E 2027 * -4.74x
Enterprise Value 90.7M 80.59M 75.22M 68.56M 129M 8.72B 131M 910M 353M 4.46B 341M 333M 14.31B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
69.08%
Yield 2026 *
-
Yield 2027 * -
1 day+1.91%
1 week+2.77%
Current month-0.70%
1 month+1.21%
3 months+8.00%
6 months+102.61%
Current year+211.18%
1 week 16.55
Extreme 16.55
17.24
1 month 16.45
Extreme 16.45
17.24
Current year 3.67
Extreme 3.6701
17.57
1 year 3.67
Extreme 3.6701
17.57
3 years 1.76
Extreme 1.7608
36.8
5 years 1.76
Extreme 1.7608
168
10 years 1.76
Extreme 1.7608
206.24
Manager TitleAgeSince
Chief Executive Officer 68 2023-07-31
Director of Finance/CFO 56 2023-01-31
Investor Relations Contact - -
Director TitleAgeSince
Chairman 69 2017-12-31
Director/Board Member 68 2023-07-31
Director/Board Member 60 2020-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/24/26 Exercice

Director

24,088 0.4536%
9/16/26 Exercice

Director

7,124 0.1341%
7/6/26 Exercice

Director

7,124 0.1344%
Change 5-day change 1-year change 3-year change Capi.($)
+1.91%+2.77%+277.94%-38.56% 90.7M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.01%-0.25%+75.17%+111.83% 39.06B
Weighted average by Cap. +0.12%-0.84%+57.01%+138.22%

Financials

2026 *2027 *
Net sales - -
Net income -25.6M -22.75M -21.23M -19.35M -36.49M -2.46B -36.83M -257M -99.55M -1.26B -96.12M -94.03M -4.04B -26.5M -23.55M -21.98M -20.03M -37.78M -2.55B -38.13M -266M -103M -1.3B -99.49M -97.33M -4.18B
Net Debt - -
Logo Rallybio Corporation
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Employees
7
Date Price Change Volume
26-10-02 US$17.08 +1.91% 7,853
26-10-01 US$16.76 -2.56% 7,081
26-09-30 US$17.20 -0.12% 5,964
26-09-29 US$17.22 +1.00% 16,685
26-09-28 US$17.05 +2.59% 16,070

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RLYB Stock